Are lab-grown brain tissues ethical? There is no no-brainer answer
Insights into ethical and legal ramifications of growing brain organoids from human fetal brain tissue
Brain organoids, though often referred to as “mini brains,” are not truly human brains. But the concerns over these lab-grown brain tissues, especially when they are developed from human fetal tissues, can be very human indeed.
Researchers from the Graduate School of Humanities and Social Sciences at Hiroshima University offer valuable insights into the complexities inherent in brain organoid research, making significant contributions to the ongoing discourse surrounding this innovative biotechnology and paving the way for informed decision-making and legal and ethical stewardship in the pursuit of scientific advancement.
Their paper was published on March 4 in EMBO Reports.
Brain organoids are three-dimensional human brain tissues derived from stem cells, which are capable of developing into many different cell types. They replicate the complexity of the human brain in a laboratory setting, allowing researchers to study brain development and diseases in the hopes of acquiring vital insights and making innovative medical advancements.
Traditionally, brain organoids are grown from pluripotent stem cells, an especially potent sub-type that is typical of early embryonic development, but new technologies now make it possible to generate these organoids from human fetal brain cells. This method comes, however, with even more heated legal and ethical debates about brain organoids — debates that are already intense in conventional organoid research.
“Our research seeks to illuminate previously often-overlooked ethical dilemmas and legal complexities that arise at the intersection of advanced organoid research and the use of fetal tissue, which is predominantly obtained through elective abortions,” said Tsutomu Sawai, an associate professor at Hiroshima University and lead author of the study.
The study highlights the urgent need for a sophisticated and globally harmonized regulatory framework tailored to navigate the complex ethical and legal landscape of fetal brain organoid (FeBO) research. The paper emphasizes the importance of informed consent protocols, ethical considerations surrounding organoid consciousness, transplantation of organoids into animals, integration with computational systems, and broader debates related to embryo research and the ethics of abortion.
“Our plan is to vigorously advocate for the development of thorough ethical and regulatory frameworks for brain organoid research, including FeBO research, at both national and international levels,” said Masanori Kataoka, a fellow researcher at Hiroshima University.
“Rather than being limited to issues of consciousness, it’s imperative, now more than ever, to systematically advance the ethical and regulatory discussion in order to responsibly and ethically advance scientific and medical progress,” Sawai said.
Moving forward, the research duo plans to continue supporting the advancement of ethical and regulatory discussions surrounding brain organoid research. By promoting responsible and ethical progress in science and medicine, they aim to ensure that all research involving brain organoids, including FeBOs, is conducted within a framework that prioritizes human dignity and ethical integrity.
###
About Hiroshima University
Since its foundation in 1949, Hiroshima University has striven to become one of the most prominent and comprehensive universities in Japan for the promotion and development of scholarship and education. Consisting of 12 schools for undergraduate level and 4 graduate schools, ranging from natural sciences to humanities and social sciences, the university has grown into one of the most distinguished comprehensive research universities in Japan. English website: https://www.hiroshima-u.ac.jp/en
JOURNAL
EMBO Reports
ARTICLE TITLE
The ethical and legal challenges of human foetal brain tissue-derived organoids: At the intersection of science, ethics, and regulation
Tiny brain bubbles carry complete codes
Scientists at Sanford Burnham Prebys demonstrated that vesicles traveling between cells in the brain carry more complete instructions for altering cellular function than previously thought.
IMAGE:
THIS PORTRAIT OF EXTRACELLULAR VESICLES WAS TAKEN USING CONFOCAL LASER SCANNING MICROSCOPY. THE MEMBRANE WAS STAINED WITH FLUORESCENT DYE. IMAGE TITLED “Exosomes” COURTESY OF TOMAĊ½ EINFALT, UNIVERSITY OF BASEL, UNDER Creative Commons BY-NC-ND license.
view moreCREDIT: TOMAĊ½ EINFALT
In findings published in Cell Reports, senior author Jerold Chun, M.D., Ph.D., and team also discovered that the biological instructions within these vesicles differed significantly in postmortem brain samples donated from patients suffering from Alzheimer’s disease.
Researchers call the tiny brain bubbles under scrutiny in this study small extracellular vesicles (sEVs). These tiny biological water balloons are produced by most cells in the body to ferry a wide variety of proteins, lipids and byproducts of cellular metabolism, as well as RNA nucleic acid codes used by recipient cells to construct new proteins.
Because this biologically active cargo can easily elicit changes in other cells, scientists are interested in brain sEVs as a medium for passing along normal as well as bungled instructions for misfolded proteins that accumulate in the brain as neurodegenerative diseases such as Alzheimer’s disease progress.
To be a potential contributor to the buildup of unwanted proteins, sEVs would have to carry blueprints with sufficient information to enable other cells to produce the problematic proteins. Most previous research had indicated that the messenger RNA (mRNA) carrying plans for proteins were chopped into too many shorter fragments to allow recipient cells to change their construction patterns.
“We found quite the opposite to be true in our study,” says Chun, professor in the Center for Genetic Disorders and Aging Research at Sanford Burnham Prebys. “We identified more than 10,000 full-length mRNAs through the use of a relatively newer DNA sequencing technique called PacBio long-read sequencing.”
The team isolated sEVs from the prefrontal cortex of 12 postmortem brain samples donated from patients diagnosed with Alzheimer’s disease and 12 from donors without Alzheimer’s disease (or any other known neurological disease). Nearly 80% of identified mRNAs were full-length, allowing them to be transcribed by recipient cells into viable proteins.
“To corroborate the results of long-read sequencing in the human samples, we also looked at vesicles isolated from mouse cells,” says first author Linnea Ransom, Ph.D., postdoctoral fellow at Sanford Burnham Prebys. “We found similar averages of between 78% and 86% full-length transcripts in three brain cell types: astrocytes, microglia and neurons.”
In addition to analyzing and validating the results regarding the length of mRNAs in brain sEVs, the researchers compared the sequence of genes reflected in the sEV mRNA transcriptome. In Alzheimer’s disease samples, 700 genes showed increased expression whereas nearly 1500 were found to have reduced activity.
The scientists determined that the 700 upregulated genes are associated with inflammation and immune system activation, which fits within known patterns of brain inflammation present in neurodegenerative diseases such as Alzheimer’s disease. The researchers also found many genes associated with Alzheimer’s disease in prior genome-wide association studies also were present in Alzheimer’s disease sEVs.
“The changes in gene expression contained in these vesicles reveal an inflammatory signature that may serve as a window into disease processes occurring in the brain as Alzheimer’s disease progresses,” says Chun.
Following this study, Chun and team will dig deeper into how cells package sEVs and how the enclosed mRNA codes lead to functional changes in other brain cells affected in Alzheimer’s disease. Better understanding of sEVs and their mRNA contents may enable the discovery of biomarkers that could be used to improve early detection of Alzheimer’s disease and potentially other neurological conditions, while identifying new disease mechanisms to provide new therapeutic targets.
“Additionally, sEVs naturally occur as a vehicle for transporting biologically active cargo between cells, so it also may be possible to leverage them as a targeted delivery system for future brain therapies” says Chun.
Additional authors on the study include Linnea S. Ransom, Christine S. Liu, Emily Dunsmore, Carter R. Palmer, Juliet Nicodemus, Derya Ziomek and Nyssa Williams, all at Sanford Burnham Prebys.
The study was supported by the National Institute on Aging (R01AG065541 and R01AG071465), National Institute of General Medical Sciences (T32GM007752) and Rotary International.
The study’s DOI is 10.1016/j.celrep.2024.114061.
Immunofluorescence was used to validate primary cell culture purity. Image courtesy of the Chun lab.
Negative-stain transmission electron microscopy was used to confirm the isolation of small extracellular vesicles in mouse neurons (shown above), as well as in mouse astrocytes and microglia. Image courtesy of the Chun lab.
Negative-stain transmission electron microscopy was used to confirm the isolation of small extracellular vesicles in mouse neurons (shown above), as well as in mouse astrocytes and microglia. Image courtesy of the Chun lab.
CREDIT
The Chun lab
The Chun lab
JOURNAL
Cell Reports
METHOD OF RESEARCH
Experimental study
SUBJECT OF RESEARCH
Human tissue samples
ARTICLE TITLE
Human brain small extracellular vesicles contain selectively packaged, full-length mRNA
ARTICLE PUBLICATION DATE
4-Apr-2024
COI STATEMENT
J.C. has been or is a consultant or scientific advisory board member or has received research support for projects unrelated to the current work from the following: Aardvark Therapeutics, Aardwolf Therapeutics, Abbott/Abbvie, Amira Pharmaceuticals, Arena Pharmaceuticals, Autobahn Therapeutics, Biogen Idec, BrainStorm Cell Therapeutics, Bristol Myers Squibb, Celgene, GSK, Inception Sciences, Janssen Research and Development, Longboard Pharmaceuticals, MindX, Mitsubishi Tanabe, Neurocrine Biosciences, Novartis Pharmaceuticals, Ono Pharmaceuticals, Pfizer, Pipeline Therapeutics, RuiYi, ShouTi, Simulyve International, Structure Therapeutics, Taisho Pharmaceutical Co., Travecta Therapeutics, Trevena, and Vial. J.C. has an employment relationship with Neurocrine Biosciences, a company that may potentially benefit from the research results. J.C.’s relationship with Neurocrine Biosciences has been reviewed and approved by the Sanford Burnham Prebys Medical Discovery Institute in accordance with its conflict of interest policies.
No comments:
Post a Comment